Nitrosamines are a group of chemical compounds known for their carcinogenic properties. These compounds can unintentionally form as impurities during the manufacturing of various substances, including active pharmaceutical ingredients (APIs). With the FDA and global health authorities strengthening regulatory requirements after several prominent recalls of widely used medications, the spotlight on nitrosamines has intensified. For pharmaceutical companies, the stakes are high. The presence of nitrosamines in drug products on the market can trigger recalls, causing severe financial and reputational damage. Moreover, during the approval process of a new drug, insufficient data on nitrosamines can lead to costly delays. Proactively managing nitrosamine risks is an imperative for drug developers to ensure compliance with regulations, maintain product safety, and uphold public trust.